Login / Signup

Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer.

Toshiki MasuishiHiroya TaniguchiDaisuke KotaniHideaki BandoYoshito KomatsuEiji ShinozakiTakako Eguchi NakajimaTaroh SatohTomohiro NishinaTaito EsakiMasashi WakabayashiShogo NomuraKoji TakahashiHiromi OnoNami HiranoNoriko FujishiroNozomu FuseAkihiro SatoAtsushi OhtsuTakayuki Yoshino
Published in: ESMO open (2019)
UMIN000031221 and 000031552.
Keyphrases
  • metastatic colorectal cancer
  • phase ii study
  • open label
  • locally advanced
  • clinical trial
  • wild type
  • squamous cell carcinoma
  • radiation therapy
  • cross sectional
  • metastatic breast cancer